When will revenues be generated with these developments?
We expect to see an revenues in 2007 with the launch of our own brands of our developments through Dexo LLC. In addition, these developments are being partnered with other partners in territories throughout the world. Significant interest has been generated in our development pipeline. BioProgress has increased its business development resources with over 25 distributors in late stage discussions. These will bring revenues either as milestones, supply agreements or profit shares early in 2007.
When will BioProgress start receiving revenues from SoluPol technology?
BioProgress will be receiving revenues based upon development milestones in early 2007 working with partners. It is anticipated that commercial revenues will commence in late 2007. SoluPol technology will be applied to novel formulations of products that have been recently acquired within the United States of America.
Are there any developments using SoluPol technology?
SoluPol was developed as a response to enquiries with our customers. The manufacture of the liquids utilise substantially the same equipment as that used for film manufacturing. Instead of pumping the liquid onto the film line, it is pumped into bottles.
BioProgress has confirmed one partner already and are in negotiations with several other pharmaceutical companies for development of novel liquids.
When will BioProgress receive revenues?
BioProgress will be receiving revenues immediately from the existing product base and will make a net profit contribution to Group revenues in 2006. Products have been developed in anticipation of the acquisition and are looking to launch Soluleaves™ formulations in time for the 2007 Cough and Cold season. Products are currently being developed using BioProgress's new SoluPol enabling technology platform
BioProgress anticipate transferring these branded products out of the US subject to regulatory approvals.
Bioprogress stock quotes
Bioprogress stock charts
Follow this thread
